In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback